Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-F1202 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-F1202 | EXPERIMENTAL | Randomized as described in the protocol Escalating Cohorts including Optional Cohorts |
| Placebo | EXPERIMENTAL | Randomized as described in the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-F1202 | DRUG | Administered per the protocol |
| Matching Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has a body mass index between 18 and 32 kg/m2, inclusive 2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of i...
ALN-F1202 is an investigational small molecule therapeutic being developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
ALN-F1202 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol REGN. Regeneron is the sponsor of the clinical program for this investigational small molecule asset.
ALN-F1202 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA for any indication.
ALN-F1202 has been evaluated in one Phase 1 trial, NCT06669234, titled a Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults. The trial was completed, enrolled 56 participants, was randomized, double-blind, and controlled, and was conducted in Belgium.
ALN-F1202 is an investigational drug and does not have a disclosed therapeutic indication. Its only reported clinical study was conducted in healthy adult volunteers rather than in patients with a specific disease, so no approved or intended use has been publicly stated.